Malignant hyperthermia: what we may need to have at hand

Rincón-Valenzuela DA, Gómez-Ardila C. Cost-benefit relationship of keeping dantrolene stocks from the point of view of healthcare institutions. Colombian Journal of Anesthesiology. 2020;48(2):63-0. doi: https://doi.org/10.1097/CJ9.0000000000000147

Glahn KPE, Bendixen D, Girard T, Hopkins PM, Johannsen S, Rüffert H, et al. Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines. Br J Anaesth. 2020;125(2):133- 140. doi: https://doi.org/10.1016/j.bja.2020.04.089

SADEA. Flujograma para la atención inicial de la crisis de hipertermia maligna. [Internet]. [Accessed on February 21, 2021]. Available at: http://sadea.com.co/hipertermia-maligna/.

Giraldo-Gutiérrez DS, Arrendo-Verbel MA, Rincón-Valenzuela DA. Dantrolene reconstitution: description of a simulation model in malignant hyperthermia. Colombian Journal of Anesthesiology. 2018;46(2):152-8. doi: https://doi.org/10.1097/CJ9.0000000000000028

Riazi S, Kraeva N, Hopkins PM. Updated guide for the management of malignant hyperthermia. Can J Anaesth. 2018;65(6):709-721. doi: https://doi.org/10.1007/s12630-018-1108-0